Literature DB >> 2498436

Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro.

J S Kühl1, R Klapdor, H Mohr, H Arps, M Dietel.   

Abstract

A panel of 10 digestive tract carcinoma cell lines (6 pancreatic carcinomas) was assayed for their sensitivity to HuLeIFN, human rIFN-gamma, rTNF-alpha and allogeneic human LAK-cells in vitro. In addition, a combination of rIFN-gamma + rTNF-alpha was tested on 3 pancreatic carcinoma cell lines. Whereas 6/7 cell lines were completely resistant to HuLeIFN, rIFN-gamma and rTNF-alpha did inhibit growth of some carcinomas tested. The individual sensitivity was heterogenous as is already known from cytostatics. Response to rIFN-gamma tended to increase with increment of cell doubling time. Only high concentrations (greater than 1000 U/ml) of rIFN-gamma displayed cytotoxicity on sensitive tumors. The antitumoral effect of rIFN-gamma was stimulated by rTNF-alpha. As revealed by isobole analysis this interaction was synergistic in all pancreatic carcinomas tested. In comparison to rIFN-gamma or rTNF-alpha the response to LAK-cells was slightly superior at high effector target ratios, even though heterogenous.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498436     DOI: 10.1007/bf02931322

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  20 in total

1.  Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.

Authors:  K Okuno; H Takagi; T Nakamura; Y Nakamura; Z Iwasa; M Yasutomi
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

2.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.

Authors:  L Fransen; J Van der Heyden; R Ruysschaert; W Fiers
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

Review 3.  Criteria for analyzing interactions between biologically active agents.

Authors:  M C Berenbaum
Journal:  Adv Cancer Res       Date:  1981       Impact factor: 6.242

4.  Cytokines and pancreatic cancer. Sensitivity of xenotransplants of predominantly pancreatic carcinomas to rIFN-gamma and rTFN-alpha in nude mice.

Authors:  J S Kühl; R Klapdor; M Bahlo; N Franke; C Kunde; H Arps; M Dietel
Journal:  Int J Pancreatol       Date:  1989-04

5.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

6.  Cell cycle-specific effects of tumor necrosis factor.

Authors:  Z Darzynkiewicz; B Williamson; E A Carswell; L J Old
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.

Authors:  B D Williamson; E A Carswell; B Y Rubin; J S Prendergast; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

8.  Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.

Authors:  A A Rayner; E A Grimm; M T Lotze; E W Chu; S A Rosenberg
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

9.  Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera.

Authors:  M Dietel; H Arps; R Klapdor; S Müller-Hagen; M Sieck; L Hoffmann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.

Authors:  R Kurzrock; M G Rosenblum; S A Sherwin; A Rios; M Talpaz; J R Quesada; J U Gutterman
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.